Search | CATIE - Canada's source for HIV and hepatitis C information

Jump to Navigation Jump to Content

Sort Results

Filter by Specific Population

Women (1)

Filter by Topic

Treatment (remove)
- HIV drugs (remove)
  - Biktarvy (remove)
  - Atazanavir (Reyataz) (1)
  - Darunavir (Prezista) (1)
  - Triumeq (1)
- Drug treatment strategies (2)

Filter by Infection

HIV (6)

Filter by Resource Category

Search results

Current filters: Treatment, HIV drugs, Biktarvy

6 search results

Biktarvy begins to get listed on provincial drug formularies: From TreatmentUpdate 233
2019, CATIE
Research summary - Webpage
Biktarvy: 2018, CATIE
Fact sheet - Webpage
Biktarvy in women with HIV: From TreatmentUpdate 228
2018, CATIE
Research summary - Webpage
Switching from Triumeq to Biktarvy: From TreatmentUpdate 228
2018, CATIE
Research summary - Webpage
Switching to Biktarvy from a protease inhibitor–based regimen: From TreatmentUpdate 228
2018, CATIE
Research summary - Webpage
Biktarvy becomes a treatment option in Canada: From TreatmentUpdate 228
2018, CATIE
Research summary - Webpage

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.

We comply with the HONcode standard for trustworthy health information: verify here.

Please note that some content on this website contains language, information and images related to sexuality and drug use, and may not be intended for people of all ages. CATIE ensures that these resources, developed to help prevent the transmission of HIV, hepatitis C and other infections, are written and reviewed by health experts for content accuracy.